Structure of Atovaquone
CAS No.: 95233-18-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
Synonyms: Atavaquone; BW 566C; Wellvone
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 95233-18-4 |
Formula : | C22H19ClO3 |
M.W : | 366.84 |
SMILES Code : | O=C1C([C@H]2CC[C@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=C1C=CC=C4)=O |
Synonyms : |
Atavaquone; BW 566C; Wellvone
|
MDL No. : | MFCD00889188 |
InChI Key : | BSJMWHQBCZFXBR-UHFFFAOYSA-N |
Pubchem ID : | 74989 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
H1299 cells | 10 µM | 24 hours | Inhibits HSP accumulation, thereby suppressing thermotolerance | PMC4962491 |
J774 mouse macrophages, human foreskin fibroblasts (HFF), murine bone marrow-derived hematopoietic progenitors | >10μM | To evaluate the cytotoxicity of ELQ-300 and P4Q-391, showing no significant cytotoxicity at concentrations 400-1000 times higher than their antimalarial activity. | PMC4227885 | |
Plasmodium falciparum (D6, 3D7, Dd2, W2, TM90-C2B) | 1.3 to 13.6 nM (ELQ-300), 3.18 to 32.3 nM (P4Q-391) | 72 hours | To evaluate the in vitro antimalarial activity of ELQ-300 and P4Q-391 against various Plasmodium strains, showing high potency against multiple strains including atovaquone-resistant isolates. | PMC4227885 |
Plasmodium falciparum NF54 (Y268S mutant) | 9.0 µM (EC50) | 72 hours | Determine the drug resistance of Y268S mutant to Atovaquone, EC50 was 9.0 µM, showing significant increase in resistance | PMC10570281 |
Plasmodium falciparum NF54 (wild type) | 0.68 nM (EC50) | 72 hours | Determine the sensitivity of wild-type parasites to Atovaquone, EC50 was 0.68 nM | PMC10570281 |
Plasmodium falciparum (NF54e/V259L) | 35.3 ± 2.5 nM | Determine the half maximal inhibitory concentration (IC50) of Atovaquone against malaria parasites | PMC5149070 | |
Plasmodium falciparum (NF54e/M133I) | 16.2 ± 3.9 nM | Determine the half maximal inhibitory concentration (IC50) of Atovaquone against malaria parasites | PMC5149070 | |
Plasmodium falciparum (NF54e) | 2.25 ± 1.13 nM | Determine the half maximal inhibitory concentration (IC50) of Atovaquone against malaria parasites | PMC5149070 | |
HCT116 cells | 10 µM | 24 hours | To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of HCT116 cells. | PMC4962491 |
FaDu cells | 10 µM | 24 hours | To evaluate the effect of CPI-455 alone and in combination with olaparib and cisplatin on cell viability. CPI-455 showed minimal effect on FaDu cell viability when used alone but was active at high concentrations (>50 µM). | PMC4962491 |
MC38 cells | 1 µM | 48 hours | To assess the impact of AZD1080 on MC38 cell viability, results showed that only the LLC cell line showed decreased viability at a high dose (100 μg/mL) of AZD1080, while slightly enhancing the viability of MC38 and CT26 cells at 10 and 100 μg/mL. | PMC8487475 |
Infected RBCs | 10 µM | 48 hours | To evaluate the growth inhibition of B. microti exposed to atovaquone, results showed significant anti-B. microti activity of atovaquone. | PMC4925016 |
CT26 cells | 15 µM and above | 24 hours | To assess the impact of AZD1080 on CT26 cell viability, results showed slightly enhancing the viability at 10 and 100 μg/mL. | PMC10784292 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
HuHep mice (FRG KO (Fah–/–, Rag2–/–, Il2rg–/–)) | Humanized mouse model (engrafted with human hepatocytes and erythrocytes) | Mosquito bite transmission | Single bite, monitored for 7.5 days | Evaluate the transmission capability of Y268S mutant parasites via mosquitoes to humanized mice, results showed mutants failed to transmit | PMC10570281 | |
Nude mice | FaDu and HCT116 xenografts | Oral | 50 mg/kg/day | Once daily for 7 days | Atovaquone significantly reduces hypoxia in FaDu and HCT116 xenografts and causes a significant tumour growth delay when combined with radiation. | PMC4962491 |
BALB/c nude mice and NOD/SCID mice | Colon cancer PDX model and MC38 homograft model | Intraperitoneal injection | 6 mg/kg and 60 mg/kg | Once daily for 7 days | To evaluate the effect of HSA-ATO NPs on alleviating tumor hypoxia and its synergistic effect with anti-PD-1 therapy, results showed that HSA-ATO NPs significantly alleviated tumor hypoxia and enhanced the efficacy of anti-PD-1 immunotherapy | PMC8487475 |
Mice | Malaria model | Intraperitoneal injection | 0.5 mg/kg | Single dose | Evaluate the transmission-blocking effect of atovaquone on malaria, results show that atovaquone can eliminate Plasmodium infection at low transmission intensities | PMC3674233 |
SCID mice | B. microti infection model | Oral gavage | 10 mg/kg | Once daily for 7 consecutive days | To evaluate the in vivo efficacy of atovaquone against B. microti infection, results showed potent activity of atovaquone at 10 mg/kg. | PMC4925016 |
BALB/c nude mice | Subcutaneous FaDu hypopharyngeal squamous cell carcinoma model | Oral administration in drinking water | 50 mg/kg/d | Once daily for 7 days | Atovaquone altered tumour pH by reducing tumour hypoxia, and APT MRI showed the associated change in tumour pH. | PMC6462213 |
Mice | Malaria infection model | Intraperitoneal injection | 1.44 mg/kg body weight | Once daily, during treatment | To evaluate the enhanced sensitivity of PV5-deregulated parasites to Atovaquone, results showed that PV5-deregulated P. berghei exhibited significantly increased sensitivity to Atovaquone | PMC7368307 |
Balb/c mice | CT26 colorectal cancer model | Oral gavage | 200 mg/kg/day | Once daily for 15 days | To evaluate the effect of Atovaquone in combination with anti-PD-L1 antibody, results showed Atovaquone significantly alleviated tumor hypoxia and synergized with anti-PD-L1, improving tumor eradication rates | PMC10784292 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03163121 | Malaria | Phase 1 | Recruiting | October 2018 | Netherlands ... More >> Leiden University Medical Center, Albinusdreef 2 Recruiting Leiden, Netherlands, 2333 ZA Contact: Leo G. Visser, MD 31715266354 l.g.visser@lumc.nl Contact: Meta Roestenberg, MD, PhD 31715264400 M.Roestenberg@lumc.nl Principal Investigator: Leo G. Visser, MD Radboud University Medical Center, Geert Grooteplein 28 Recruiting Nijmegen, Netherlands, 6525 GA Contact: Robert W. Sauerwein, MD 31243610577 Robert.Sauerwein@radboudumc.nl Contact: Jona Walk, MD 31243613663 Jona.Walk@radboudumc.nl Principal Investigator: Robert W. Sauerwein, MD Less << |
NCT01218893 | Plasmodium Falciparum Malaria | Not Applicable | Completed | - | Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2300 RC Less << |
NCT01236612 | Plasmodium Falciparum Malaria | Not Applicable | Completed | - | Netherlands ... More >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB Less << |
NCT01422954 | Malaria Plasm... More >>odium Falciparum Less << | Not Applicable | Completed | - | Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2333 ZA Less << |
NCT00149383 | Falciparum Malaria | Phase 1 Phase 2 | Completed | - | Thailand ... More >> Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand, 10400 Less << |
NCT03454048 | Malaria,Falciparum ... More >> Gametocytes Controlled Human Malaria Infection Transmission Less << | Not Applicable | Recruiting | December 1, 2018 | Netherlands ... More >> Radboud university medical center Recruiting Nijmegen, Gelderland, Netherlands, 6525 GA Contact: Isaie Reuling 024 361 9515 ext +31 isaie.reuling@radboudumc.nl Less << |
NCT03083847 | Malaria | Phase 1 | Recruiting | June 30, 2019 | United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov Less << |
NCT02098590 | Malaria | Not Applicable | Completed | - | Netherlands ... More >> Radboud university medical center Nijmegen, Gelderland, Netherlands, 6525 GA Less << |
NCT00298610 | Malaria | Phase 2 | Completed | - | Kenya ... More >> New Nyanza Provincial Hospital Kisumu, New Nyanza, Kenya Less << |
NCT01976325 | Malaria | Not Applicable | Unknown | November 2015 | Canada, Ontario ... More >> National Capital Region Occupational Health Clinic Recruiting Ottawa, Ontario, Canada, K1A 0K9 Contact: Louise J Levesque, RN, BScN 613-946-5533 louise.j.levesque@hc-sc.gc.ca Contact: Lisa Taras, MD, CCFP 613-946-6583 lisa.taras@hc-sc.gc.ca Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1Y 4E9 Contact: Charde A Morgan, MScPH 613-737-8899 ext 72424 cmorgan@ohri.ca Contact: Anne E McCarthy, MD 613-737-8899 ext 78184 amccarthy@toh.on.ca Principal Investigator: Anne E McCarthy, MD, MSc Sub-Investigator: Charde A Morgan, MScPH International Association for Medical Assistance to Travellers Recruiting Toronto, Ontario, Canada, M6K 3E3 Contact: Tullia Marcolongo 416-652-0137 tullia@iamat.org Less << |
NCT00451139 | Malaria | Phase 4 | Completed | - | Ethiopia ... More >> Jimma University Hospital Jimma, Ethiopia Less << |
NCT02836002 | Malaria | Phase 1 Phase 2 | Completed | - | Netherlands ... More >> Radboud university medical center Nijmegen, Gelderland, Netherlands, 6525 GA Less << |
NCT00636935 | Pneumocystis Carinii Pneumonia | Phase 4 | Withdrawn(No patient completed... More >> protocol) Less << | - | United States, District of Col... More >>umbia George Washington University Medical Faculty Associates Washington, D.C., District of Columbia, United States, 20037 Less << |
NCT01660854 | Malaria, Falciparum | Not Applicable | Completed | - | Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2333ZA Less << |
NCT01055002 | Healthy Non-s... More >>mokers Less << | Phase 1 Phase 2 | Completed | - | Australia, Queensland ... More >> Q-Pharm Clinics, Royal Brisbane and Women's Hospital Brisbane, Queensland, Australia, 4006 Less << |
NCT00298610 | - | Completed | - | - | |
NCT02564471 | Rabies | Phase 4 | Recruiting | December 2018 | United States, New York ... More >> State University of New York, Upstate Medical University (SUNY-UMU) Recruiting Syracuse, New York, United States, 13210 Contact: Lisa Ware, MS 315-464-4398 warel@upstate.edu Less << |
NCT02080026 | Malaria | Not Applicable | Completed | - | Netherlands ... More >> Radboud university medical center Nijmegen, Gelderland, Netherlands, 6525 GA Less << |
NCT00386750 | Malaria Falci... More >>parum Less << | Phase 4 | Terminated | - | - |
NCT01442168 | Malaria, Falciparum | Phase 1 Phase 2 | Terminated | - | Thailand ... More >> Mae Ramat Hospital Mae Ramat, Tak province, Thailand Maesot General hospital Mae Sot, Tak Province, Thailand Hospital for Tropical Diseases Bangkok, Thailand Less << |
NCT02450578 | Falciparum Malaria | Phase 1 | Completed | - | Germany ... More >> Universitätsklinikum Tübingen, Institut für Tropenmedizin Tübingen, Germany, 72074 Less << |
NCT02858817 | Malaria | Phase 1 | Unknown | March 2018 | - |
NCT03278808 | Malaria | Phase 2 | Recruiting | September 1, 2020 | United States, Maryland ... More >> Clinical Research Unit, Uniformed Services University of Health Sciences Not yet recruiting Bethesda, Maryland, United States, 20814 Contact: Thomas Oliver, MD 301-295-0016 thomas.g.oliver.mil@mail.mil WRAIR Recruiting Silver Spring, Maryland, United States, 20910 Contact: Jeffrey R Livezey, MD 301-319-3217 jeffrey.r.livezey.mil@mail.mil Less << |
NCT00444106 | Malaria Falci... More >>parum Less << | Phase 4 | Completed | - | Colombia ... More >> Novartis Investigational Site Tumaco, Colombia Less << |
NCT00000811 | Bacterial Infections ... More >> Pneumonia, Pneumocystis Carinii HIV Infections Less << | Phase 2 | Completed | - | - |
NCT01150344 | Malaria | Phase 4 | Completed | - | France ... More >> Hôpital Avicenne Bobigny, Seine St Denis, France, 93000 Less << |
NCT00379821 | Plasmodium Falciparum Infectio... More >>n Less << | Phase 3 | Completed | - | Malawi ... More >> Blantyre Malaria Project - Ndirande Health Centre Blantyre, Malawi Less << |
NCT00444106 | - | Completed | - | - | |
NCT00000794 | Toxoplasmosis, Cerebral ... More >> HIV Infections Less << | Phase 2 | Completed | - | United States, California ... More >> USC CRS Los Angeles, California, United States, 900331079 United States, Florida Univ. of Miami AIDS CRS Miami, Florida, United States, 331361013 United States, Hawaii Queens Med. Ctr. Honolulu, Hawaii, United States, 96816 Univ. of Hawaii at Manoa, Leahi Hosp. Honolulu, Hawaii, United States, 96816 United States, Illinois Northwestern University CRS Chicago, Illinois, United States, 60611 Cook County Hosp. CORE Ctr. Chicago, Illinois, United States, 60612 United States, Indiana Indiana Univ. School of Medicine, Infectious Disease Research Clinic Indianapolis, Indiana, United States, 462025250 Methodist Hosp. of Indiana Indianapolis, Indiana, United States, 46202 United States, Maryland Johns Hopkins Adult AIDS CRS Baltimore, Maryland, United States, 21287 United States, Missouri Washington U CRS St. Louis, Missouri, United States, 63110 St. Louis ConnectCare, Infectious Diseases Clinic St. Louis, Missouri, United States United States, New York SUNY - Buffalo, Erie County Medical Ctr. Buffalo, New York, United States, 13210 Beth Israel Med. Ctr. (Mt. Sinai) New York, New York, United States, 10003 NY Univ. HIV/AIDS CRS New York, New York, United States United States, Ohio Univ. of Cincinnati CRS Cincinnati, Ohio, United States, 452670405 The Ohio State Univ. AIDS CRS Columbus, Ohio, United States, 432101228 Less << |
NCT00001994 | Toxoplasmosis, Cerebral|HIV In... More >>fections Less << | COMPLETED | - | Los Angeles County - USC Med C... More >>tr, Los Angeles, California, 90033, United States|Infectious Disease Med Group, Oakland, California, 94609, United States|San Francisco Gen Hosp, San Francisco, California, 941102859, United States|UCSF - San Francisco Gen Hosp, San Francisco, California, 94110, United States|Davies Med Ctr, San Francisco, California, 94114, United States|Georgetown Univ Med Ctr, Washington, District of Columbia, 20007, United States|Infectious Disease Research Consortium of Georgia, Atlanta, Georgia, 30345, United States|Johns Hopkins Hosp, Baltimore, Maryland, 21205, United States|Beth Israel Med Ctr, New York, New York, 10003, United States|Saint Vincent's Hosp and Med Ctr, New York, New York, 10011, United States|Harlem Hosp Ctr, New York, New York, 10037, United States|SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, 117948153, United States|Duke Univ Med Ctr, Durham, North Carolina, 27710, United States|Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland, Oregon, 97210, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, 38103, United States|Gathe, Joseph, M.D., Houston, Texas, 77004, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Infectious Disease Physicians Inc, Annandale, Virginia, 22203, United States|Southern Alberta HIV Clinic / Foothills Hosp, Calgary, Alberta, Canada|Dr Julio S G Montaner, Vancouver, British Columbia, Canada|Wellesley Hosp, Toronto, Ontario, Canada|Dr Emil Toma / Hotel Dieu de Montreal, Montreal, Quebec, Canada Less << | |
NCT00000655 | Pneumonia, Pneumocystis Carini... More >>i HIV Infections Less << | Phase 2 | Completed | - | - |
NCT00379821 | - | Completed | - | - | |
NCT00084227 | Malaria, Falciparum | Phase 2 Phase 3 | Completed | - | - |
NCT00001991 | Pneumonia, Pneumocystis Carini... More >>i|HIV Infections Less << | COMPLETED | - | Glaxo Wellcome Inc, Research T... More >>riangle Park, North Carolina, 27709, United States Less << | |
NCT00001990 | Pneumonia, Pneumocystis Carini... More >>i|HIV Infections Less << | COMPLETED | - | Glaxo Wellcome Inc, Research T... More >>riangle Park, North Carolina, 27709, United States Less << | |
NCT00001996 | Pneumonia, Pneumocystis Carini... More >>i HIV Infections Less << | Phase 2 | Completed | - | United States, California ... More >> East Bay AIDS Ctr Berkeley, California, United States, 94704 Kaiser Foundation Hosp Harbor City, California, United States, 90710 Cedars Sinai Med Ctr Los Angeles, California, United States, 90048 UCLA CARE Ctr Los Angeles, California, United States, 90095 UCI Med Ctr Orange, California, United States, 92668 AIDS Community Research Consortium Redwood City, California, United States, 94063 Davies Med Ctr San Francisco, California, United States, 94114 Dr Patrick Joseph San Ramone, California, United States, 94583 United States, Georgia Infectious Disease Research Consortium of Georgia Atlanta, Georgia, United States, 30345 United States, Massachusetts Massachusetts Gen Hosp Boston, Massachusetts, United States, 02114 Boston City Hosp Boston, Massachusetts, United States, 02118 United States, New York Beth Israel Med Ctr New York, New York, United States, 10003 Saint Vincent's Hosp and Med Ctr New York, New York, United States, 10011 Harlem AIDS Treatment Group / Harlem Hosp Ctr New York, New York, United States, 10037 United States, Ohio Univ of Cincinnati Cincinnati, Ohio, United States, 452670405 United States, Oregon Portland Veterans Adm Med Ctr / Rsch & Education Grp Portland, Oregon, United States, 97210 United States, Pennsylvania Buckley Braffman Stern Med Associates Philadelphia, Pennsylvania, United States, 19107 United States, Tennessee Regional Med Ctr at Memphis Memphis, Tennessee, United States, 38103 United States, Texas Gathe, Joseph, M.D. Houston, Texas, United States, 77004 Baylor College of Medicine Houston, Texas, United States, 77030 Less << |
NCT00000802 | Pneumonia, Pneumocystis Carini... More >>i HIV Infections Less << | Phase 3 | Completed | - | - |
NCT03726593 | Plasmodium Falciparum Malaria ... More >>(Drug Resistant) Less << | Phase 4 | Recruiting | June 30, 2021 | Cambodia ... More >> Kratie Referral Hospital Not yet recruiting Kratie, Cambodia Contact: Somaly Kieng, M.D +855 72 971 755 Contact: Chanthap Lon, M.D 855 23 881 845 chanthapl@afrims.org Sub-Investigator: Darapiseth Sea, MD Sub-Investigator: Dysoley Lek, MD Anlong Veng Referral Hospital Recruiting Ânlóng Vêng, Cambodia Contact: Phan Kong, M.A 016 51 09 09 Principal Investigator: Chanthap Lon, MD Sub-Investigator: Darapiseth Sea, MD Sub-Investigator: Dysoley Lek, MD Less << |
NCT00002340 | Pneumonia, Pneumocystis Carini... More >>i HIV Infections Less << | Phase 3 | Completed | - | United States, Florida ... More >> Goodgame Med Group Maitland, Florida, United States, 32751 Bay Area AIDS Consortium Tampa, Florida, United States, 33609 United States, New York Saint Vincent's Hosp and Med Ctr New York, New York, United States, 10011 United States, Ohio Holmes Hosp Cincinnati, Ohio, United States, 452670405 United States, Virginia Hampton Roads Med Specialists Hampton, Virginia, United States, 23666 Less << |
NCT00000773 | Pneumonia, Pneumocystis Carini... More >>i|HIV Infections Less << | PHASE1 | COMPLETED | 1996-09-01 | UCSF Pediatric AIDS CRS, San F... More >>rancisco, California, 94143, United States|Chicago Children's CRS, Chicago, Illinois, 60614, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|DUMC Ped. CRS, Durham, North Carolina, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, 38105, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, 00936, Puerto Rico Less << |
NCT00421473 | HIV Infections ... More >> Malaria Less << | Phase 4 | Completed | - | Netherlands ... More >> Elisabeth hospital Tilburg, Brabant, Netherlands, 5022 GC Alysis Zorggroep loc. Rijnstate Arnhem, Gelderland, Netherlands, 6800 TA Radboud University Medical Centre Nijmegen Nijmegen, Gelderland, Netherlands, 6525 GA Leids Universitair Medisch Centrum Leiden, Zuid Holland, Netherlands, 2300 RC Erasmus MC Rotterdam, Zuid Holland, Netherlands, 3000 CA Less << |
NCT01479361 | HIV PCP ... More >> Toxoplasmosis Less << | Phase 1 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT01858831 | Malaria | Phase 1 | Completed | - | Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less << |
NCT02297477 | Malaria | Phase 4 | Active, not recruiting | February 2019 | Cambodia ... More >> Anlong Veng Referral Hospital Anlong Veng, Oddar Meancheay, Cambodia Less << |
NCT00984256 | - | Completed | - | - | |
NCT00984256 | Malaria | Phase 2 | Completed | - | United States, Maryland ... More >> Walter Reed Army Institute of Research Silver Spring, Maryland, United States, 20910 Less << |
NCT03568994 | Acute Myeloid Leukemia | Early Phase 1 | Recruiting | January 2021 | United States, Maryland ... More >> John Hopkins Medicine Not yet recruiting Baltimore, Maryland, United States, 21205 Contact: Cara Rabik, MD United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Alexandra Stevens 832-824-4824 United States, Washington Seattle Children's Hospital Not yet recruiting Seattle, Washington, United States, 98101 Contact: Todd Cooper, MD Less << |
NCT02628080 | Carcinoma, Non-Small-Cell Lung | EARLY_PHASE1 | COMPLETED | 2025-12-18 | Churchill Hospital, Oxford, Ox... More >>fordshire, OX3 7LE, United Kingdom Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.73mL 0.55mL 0.27mL |
13.63mL 2.73mL 1.36mL |
27.26mL 5.45mL 2.73mL |